Citius Oncology (NASDAQ:CTOR) Trading 6.3% Higher – Still a Buy?

Citius Oncology, Inc. (NASDAQ:CTOR) shares rose 6.3% during mid-day trading on Tuesday . The company traded as high as $0.67 and last traded at $0.66. Approximately 44,432 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 1,224,909 shares. The stock had previously closed at $0.62.

Citius Oncology Price Performance

The business has a 50 day simple moving average of $0.84 and a 200-day simple moving average of $1.04. The company has a quick ratio of 0.08, a current ratio of 0.34 and a debt-to-equity ratio of 0.08.

Citius Oncology (NASDAQ:CTOR) last issued its earnings results on Friday, February 14th. The company reported ($0.09) EPS for the quarter.

Institutional Investors Weigh In On Citius Oncology

An institutional investor recently bought a new position in Citius Oncology stock. Citadel Advisors LLC bought a new stake in Citius Oncology, Inc. (NASDAQ:CTOR) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 22,699 shares of the company’s stock, valued at approximately $26,000. 70.52% of the stock is owned by hedge funds and other institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.